These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Blanpain C; Le Poul E; Parma J; Knoop C; Detheux M; Parmentier M; Vassart G; Abramowicz MJ Cardiovasc Res; 2003 Dec; 60(3):518-28. PubMed ID: 14659797 [TBL] [Abstract][Full Text] [Related]
24. Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report. Hagiwara M; Tsuchida A; Hyakkoku M; Nishizato K; Asai T; Nozawa Y; Tsuchihashi K; Shimamoto K Jpn Circ J; 2000 Mar; 64(3):218-21. PubMed ID: 10732856 [TBL] [Abstract][Full Text] [Related]
25. Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. Tomita T; Zhao Q Chest; 2002 Feb; 121(2):649-52. PubMed ID: 11834685 [TBL] [Abstract][Full Text] [Related]
26. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Eddahibi S; Adnot S Respir Res; 2002; 3(1):9. PubMed ID: 11806844 [TBL] [Abstract][Full Text] [Related]
27. Appetite suppressants and pulmonary hypertension. Cahal DA Lancet; 1969 May; 1(7601):947. PubMed ID: 4180930 [No Abstract] [Full Text] [Related]
28. [The French are wary of their drugs]. Nau JY Rev Med Suisse; 2011 May; 7(296):1170-1. PubMed ID: 21728251 [No Abstract] [Full Text] [Related]
31. [Pulmonary hypertension following use of appetite depressants?]. Homann G Med Klin; 1974 Feb; 69(5):211. PubMed ID: 4819931 [No Abstract] [Full Text] [Related]
32. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. Palmieri V; Arnett DK; Roman MJ; Liu JE; Bella JN; Oberman A; Kitzman DW; Hopkins PN; Morgan D; de Simone G; Devereux RB Am J Med; 2002 Jun; 112(9):710-5. PubMed ID: 12079711 [TBL] [Abstract][Full Text] [Related]
33. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086 [TBL] [Abstract][Full Text] [Related]
34. High altitude may be synergistic with pulmonary hazards of appetite control medications fenfluramine and dexfenfluramine. Davis WM; Waters IW Med Hypotheses; 1997 Dec; 49(6):509-12. PubMed ID: 9466375 [TBL] [Abstract][Full Text] [Related]
36. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Schoonjans AS; Marchau F; Paelinck BP; Lagae L; Gammaitoni A; Pringsheim M; Keane MG; Ceulemans B Curr Med Res Opin; 2017 Oct; 33(10):1773-1781. PubMed ID: 28704161 [TBL] [Abstract][Full Text] [Related]
37. Fenfluramine: riddle or Rosetta stone? Weir EK; Obreztchikova M; Hong Z Eur Respir J; 2008 Feb; 31(2):232-5. PubMed ID: 18238944 [No Abstract] [Full Text] [Related]
38. Death from irreversible pulmonary hypertension associated with short-term use of fenfluramine and phentermine. Dillon KA; Putnam KG; Avorn JL JAMA; 1997 Oct 22-29; 278(16):1320. PubMed ID: 9343461 [No Abstract] [Full Text] [Related]
39. Primary pulmonary hypertension and anorectic drugs. Louis WJ N Engl J Med; 1999 Feb; 340(6):480-2. PubMed ID: 9988623 [No Abstract] [Full Text] [Related]